IS8496A - Samsetningar til meðhöndlunar á fjölgunarsjúkdómum - Google Patents

Samsetningar til meðhöndlunar á fjölgunarsjúkdómum

Info

Publication number
IS8496A
IS8496A IS8496A IS8496A IS8496A IS 8496 A IS8496 A IS 8496A IS 8496 A IS8496 A IS 8496A IS 8496 A IS8496 A IS 8496A IS 8496 A IS8496 A IS 8496A
Authority
IS
Iceland
Prior art keywords
propagating
diseases
compositions
treatment
propagating diseases
Prior art date
Application number
IS8496A
Other languages
English (en)
Icelandic (is)
Inventor
James M Nichols
Margaret S Lee
Keith Curtis
Zhang Yanzhen
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of IS8496A publication Critical patent/IS8496A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8496A 2003-11-12 2006-06-02 Samsetningar til meðhöndlunar á fjölgunarsjúkdómum IS8496A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
PCT/US2004/037527 WO2005046607A2 (fr) 2003-11-12 2004-11-09 Combinaisons pour traitement de maladies proliferatives

Publications (1)

Publication Number Publication Date
IS8496A true IS8496A (is) 2006-06-02

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8496A IS8496A (is) 2003-11-12 2006-06-02 Samsetningar til meðhöndlunar á fjölgunarsjúkdómum

Country Status (13)

Country Link
EP (1) EP1689352A2 (fr)
JP (1) JP2007524657A (fr)
KR (1) KR20060118514A (fr)
AR (1) AR046841A1 (fr)
AU (1) AU2004289311A1 (fr)
BR (1) BRPI0416390A (fr)
CA (1) CA2545423A1 (fr)
IL (1) IL175611A0 (fr)
IS (1) IS8496A (fr)
NO (1) NO20062358L (fr)
RU (1) RU2006120491A (fr)
TW (1) TW200526777A (fr)
WO (1) WO2005046607A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI675668B (zh) * 2008-03-18 2019-11-01 美商建南德克公司 抗ｈｅｒ２抗體-藥物結合物及化療劑之組合及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (fr) * 1998-06-17 1999-12-17 Paolo Renzi Oligonucleoside antisens pour traiter ou prevenir les maladies atopiques et la proliferation de cellules neoplastiques
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
IL175611A0 (en) 2008-04-13
EP1689352A2 (fr) 2006-08-16
JP2007524657A (ja) 2007-08-30
RU2006120491A (ru) 2007-12-20
WO2005046607A2 (fr) 2005-05-26
AU2004289311A1 (en) 2005-05-26
NO20062358L (no) 2006-07-12
AR046841A1 (es) 2005-12-28
WO2005046607A3 (fr) 2012-12-20
CA2545423A1 (fr) 2005-05-26
BRPI0416390A (pt) 2007-02-21
KR20060118514A (ko) 2006-11-23
TW200526777A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8516A (is) Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
IS8246A (is) Meðferð á taugahrörnunarástandi
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
NO20045554L (no) Fremgangsmate for behandling av diabetes
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
EP1611120A4 (fr) Nouvelles m thodes de traitement des maladies inflammatoires